Archived Press Releases

December 4, 2006 - Perceptronix's first ClearSign™ lung cancer testing facility [PDF]
Vancouver, Canada (December 4, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has opened its first sputum induction facility at MDS Metro Laboratory Services’ Victoria Drive Patient Service Centre in Vancouver. This facility will be the first centre to offer sputum induction for Perceptronix’s ClearSign™ Sputum Test (“ClearSign™”).

September 27, 2006 - Perceptronix attracts high profile President and CEO [PDF]
Vancouver, Canada (August 21, 2006) – The Board of Directors of Perceptronix Medical Inc. (“Perceptronix”) is pleased to announce the appointment of Mr. Carl F. Roy to the position of President and CEO, effective September 25, 2006.

August 21, 2006 - Perceptronix receives Health Canada License for early lung cancer test [PDF]
Vancouver, Canada (August 21, 2006) – Perceptronix Medical Inc. (“Perceptronix”)
announced today that it has been issued a Class III in vitro Diagnostic Device License from Health Canada for its ClearSign™ Sputum Test for the detection of early lung cancer.  Perceptronix can now market this test service in Canada as well as in the European Union, having received CE Mark registration in May, 2006.

August 14, 2006 - Perceptronix signs Contribution Agreement with National Research Council Canada [PDF]
Vancouver, Canada (August 14, 2006) – Perceptronix Medical Inc. (“Perceptronix”)
announced today that the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) has agreed to provide a financial contribution in support of the development of its ClearVu™ Elite advanced fluorescence bronchoscopy system.

June 20, 2006 - Perceptronix raises CDN$5.5M  [PDF]
Vancouver, Canada (June 20, 2006) – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver based cancer diagnostics company, announced today that it has recently raised CDN$5.5 M in private financing designed to serve as a bridge to an anticipated larger institutional private placement financing. 

May 26, 2006 - Perceptronix receives CE Mark for its ClearSign™ Sputum Test for early lung cancer  [PDF]
Vancouver, Canada (May 26, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announces receipt of C Mark for its ClearSign™ Sputum Test for the detection of early lung cancer, allowing it to be marketed in the European Union.
 
April 4, 2006 - Perceptronix receives US Food and Drug Administration Medical Device Listing and CE Mark for Clear2C™  [PDF]
Vancouver, Canada (April 4, 2006) - Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been issued a Medical Device Listing from the US Food and Drug Administration (FDA) and CE Mark for its Clear2C™ Quantitative DNA Staining Kit. Perceptronix will now begin marketing and selling this product to all laboratories requiring consistent quantitative absorbance microscopy staining in the United States, Canada, and the European Union (EU) .
 
March 30, 2006 - Perceptronix announces the opening of its first Clinical Quantitative Cytology Lab  [PDF]
Vancouver, Canada (March 30, 2006) - Perceptronix Medical Inc. ("Perceptronix") announced today the opening of its first Quantitative Cytology Laboratory in Vancouver, British Columbia, offering advanced quantitative clinical laboratory services to assist clinicians in the diagnosis and prognosis of cancer. 

February 8, 2006 - Perceptronix receives Medical Device Licenses for ClearCyte™ and Clear2C™ from Health Canada  [PDF]
Vancouver, Canada (February 8, 2006)– Perceptronix Medical Inc ("Perceptronix") announced today that it has been issued Medical Device Licenses from Health Canada for its first two products - the ClearCyte™ Quantitative Cytology System and its associated Clear2C™ Quantitative DNA Staining Kit. Perceptronix can now market these two products in Canada.
 
February 2, 2006 - Perceptronix receives CE Mark for its first product  [PDF]
Vancouver, Canada (February 2, 2006)– Perceptronix Medical Inc ("Perceptronix") announced today that it has received CE Mark for its first product – the ClearCyte™ Quantitative Pathology System, allowing it to be marketed throughout the European Union (EU).
 
January 23, 2006 - Perceptronix Commissions United Kingdom Site of International Lung Cancer DetectionTrial  [PDF]
Vancouver, Canada (January 23, 2006)– Perceptronix Medical Inc ("Perceptronix") announced today the initiation of the Coventry site to their clinical study for the ClearVuElite™ fluorescence endoscopy system for the early detection of lung cancer, raising the total trial sites to four, including; St. Petersburg Russia, Ljubljana, Slovenia and Vancouver, Canada.

December 6, 2005 - Perceptronix announces appointment of New Directors  [PDF]
Vancouver, Canada (December 6, 2005)– Perceptronix Medical Inc ("Perceptronix") announced today the resignation of one member of its Board of Directors and the addition of two new members to its Board of Directors, brining the total Board membership to six.  
October 25, 2005 - Perceptronix to present lung cancer detection test clinical trial results at international conference "CHEST 2005"  [PDF]
Vancouver, Canada (October 25, 2005)– Dr. Bojana Turic and Dr. Roger Kemp of Perceptronix Medical Inc. (“Perceptronix”) will each present a paper on the detection of lung cancer by cytometric analysis at “CHEST 2005”, the 71st annual international scientific assembly of the American College of Chest Physicians being held October 29 through November 3 in Montréal, Québec, Canada.
 
August 26, 2005 - Perceptronix announces appointment of Stephen Anderson as Chief Financial Officer.  [PDF]
Vancouver, Canada (August 26, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a cancer diagnostics medical device company, announced today the appointment of Stephen Anderson as Chief Financial Officer. Mr. Anderson’s experience
includes over five years with Westport Innovations Inc. spanning roles as Controller, Vice President, Finance and Chief Financial Officer.
 
August 25, 2005 - Perceptronix announces that results of lung cancer detection test clinical trial meet test objectives  [PDF]
Vancouver, Canada (August 25, 2005) - Perceptronix Medical Inc. (“Perceptronix”) announced today that it has unblinded its clinical trial for the ClearSign™ Test, a non-invasive test for the detection of lung cancer based on the automated cytometric analysis of sputum.  Initial analysis indicates that the clinical trial met all significant objectives and the Company is optimistic that licenses will be issued for the ClearSign™ Test early in 2006.
 
July 21, 2005 - Perceptronix receives ISO (International Organization for Standardization) quality certification. Critical requirement for obtaining licenses for product sales in Canada and Internationally.  [PDF]
Vancouver, Canada (July 21, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a cancer diagnostics medical device company, is proud to announce that it has received ISO 13485:2003 and ISO 9001:2000 certification of its quality management system for the “Design and manufacture of in vitro devices for the detection, localization and diagnosis of cancer”.  
 
July 19, 2005 - Perceptronix granted another U.S. patent for lung cancer detection technology. New technique could reduce number of negative biopsies.  [PDF]
Vancouver, Canada (July 19, 2005) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been granted patent number 6,898,458 by the United States Patent and Trademark Office, entitled; “Methods and apparatus for fluorescence and reflectance imaging and spectroscopy and for contemporaneous measurement of electromagnetic radiation with multiple measuring devices”. 
 
June 7, 2005 - Perceptronix announces election of Board of Directors.  [PDF]
Vancouver, Canada (June 7, 2005) – Perceptronix Medical Inc. (“Perceptronix”) announced today the retirement of Mr. Randall Mullan (Head of Direct Investment, British Columbia Investment Management Corporation) from its Board of Directors, the election of three new members and the re-election of three previous members to its Board at its recent Annual General Meeting of Shareholders. This brings the total Board membership to six.
 
April 20, 2005 - Asia-based manufacturing partner invests in Perceptronix.  [PDF]Vancouver, Canada, 20 April, 2005 – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver-based medical device company focused on cancer diagnostics, announced today that it has closed the private placement with Speed Fair Co. Ltd. ("Speed Fair") of Hong Kong referred to in its press release of 7 April, 2005.
 
April 7, 2005 - Cancer diagnostics device firm Perceptronix strengthens strategic alliance with Asia-based manufacturing partner.  [PDF]
Vancouver, Canada, 7 April, 2005 – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver-based medical device company focused on cancer diagnostics, announced today that it has signed a Supply Agreement with Speed Fair Co. Ltd. (“Speed Fair”) of Hong Kong.  The signing of the Supply Agreement was the last outstanding condition for the completion of an equity investment in Perceptronix by Speed Fair. ...
 
February 18, 2005 - Perceptronix earns US patent for lung cancer detection technology.  [PDF]
Vancouver, Canada, 18 February, 2005 – Perceptronix Medical Inc. (“Perceptronix”) today announced that the United States Patent and Trademark Office has granted to Perceptronix patent number 6,826,424 entitled “Methods and apparatus for fluorescence and reflectance imaging and spectroscopy and for contemporaneous measurement ...
 
January 24, 2005 - Local cancer diagnostics firm signs agreement with China-based firm during Team Canada Trade Mission.  [PDF]
Vancouver, Canada, 24 January, 2005 – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has signed a Memorandum of Understanding (“MOU”) with Speed Fair Co. Ltd. (“Speed Fair”) as part of the Hong Kong contract signing ceremony of the Prime Minister’s Team Canada Trade Mission to the People’s Republic of China.